ERBB2 and neoplasm: ,49 This is in contrast to our observations where HER2 amplification is associated with an inflammatory phenotype characterised by activation of the cGAS-STING pathway and we observe that HER2/EGFR blockade may be immunosuppressive rather than increasing tumour immune cell populations.